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Abstract
Background: We assessed the prevalence, and potential impact of, trials of pharmacological agents for acute stroke 
that were completed but not published in full. Failure to publish trial data is to be deprecated as it sets aside the 
altruism of participants' consent to be exposed to the risks of experimental interventions, potentially biases the 
assessment of the effects of therapies, and may lead to premature discontinuation of research into promising 
treatments.
Methods: We searched the Cochrane Stroke Group's Specialised Register of Trials in June 2008 for completed trials of 
pharmacological interventions for acute ischaemic stroke, and searched MEDLINE and EMBASE (January 2007 - March 
2009) for references to recent full publications. We assessed trial completion status from trial reports, online trials 
registers and correspondence with experts.
Results: We identified 940 trials. Of these, 125 (19.6%, 95% confidence interval 16.5-22.6) were completed but not 
published in full by the point prevalence date. They included 16,058 participants (16 trials had over 300 participants 
each) and tested 89 different interventions. Twenty-two trials with a total of 4,251 participants reported the number of 
deaths. In these trials, 636/4251 (15.0%) died.
Conclusions: Our data suggest that, at the point prevalence date, a substantial body of evidence that was of relevance 
both to clinical practice in acute stroke and future research in the field was not published in full. Over 16,000 patients 
had given informed consent and were exposed to the risks of therapy. Responsibility for non-publication lies with 
investigators, but pharmaceutical companies, research ethics committees, journals and governments can all 
encourage the timely publication of trial data.
Background
Completing but not publishing clinical trials in full can be
unethical[1]. Well designed clinical trials should be pub-
lished because their results can benefit patients, justifying
the risk to trial participants from experimental treat-
ments[1]. Failing to publish clinical trials can bias the
findings of systematic reviews and meta-analyses if their
findings differ from published results[2] which may lead
to inappropriate treatment decisions and health care pol-
icies[3].
Previous studies of unpublished clinical trials used
small samples of clinical trials to estimate the prevalence
of non-publication, including trial abstracts which were
submitted to one conference over three years [4-6], trials
submitted to a single research ethics committee[7,8] or a
single country's drug regulatory agency[9]. Limiting
searches for published trials to databases[4,8] may have
missed full trial reports in non-indexed journals and
books, leading such trials to be misclassified as unpub-
lished. Also ongoing trials may have been misclassified as
unpublished by failing to determine the status of clinical
trials[4,6,9]. A systematic review which identified trials of
acute ischaemic stroke only through reference lists of
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published Cochrane Stroke Group reviews found that
11% (19/178) had not been published in full as of Decem-
ber 31, 1999, although the trials had been reported in
abstracts between two and 17 years before this date[10].
The Cochrane Stroke Group's Specialised Register of
Trials is a very comprehensive database[11] which
includes over 12,000 reports relating to around 6,000
stroke trials (Brenda Thomas, personal communication,
June 2008). We used this register to perform a systematic
review of clinical trials of pharmacological interventions
for acute ischaemic stroke. We aimed to determine the
prevalence of and characteristics of completed but
unpublished trials.
Methods
Definition of 'unpublished'
We classified trials as unpublished if detailed methods
and results were not reported in either a peer-reviewed
journal article [8] or book chapter, i.e. not published in
full. We considered forms of written information includ-
ing abstracts, drug company reports, letters, literature
r evi ew s,  a n d  o n l i n e  t r i a l s  r e g i s t e r s  t o  be  l e s s  t h a n  f u l l
publications, which we term 'sources.' If it was unclear
whether a trial had or had not been published from the
titles of references, the trial source(s) were retrieved. We
considered a study in the trials register to be unpublished
if we could not match the details of study methods and
results to any subsequent full publication.
Search strategy
One author (BT) searched the Cochrane Stroke Group's
Specialised Register of Trials[12] on June 19th 2008 for tri-
als of pharmacological interventions for acute ischaemic
stroke. Another author (LG) screened the titles of refer-
ences identified from the search of the register to select
trials which appeared to be unpublished. We searched
MEDLINE and EMBASE from January 2007 to March
2009 to check for recent publications of any trials which
initially appeared to be unpublished. Duplicate trials were
removed. There were no language restrictions.
Classification of trial completion status
W e assigned a completion status of complete, ongoing,
temporarily suspended, planned, never started or unclear
to unpublished trials. We classified trials as complete if
the most recent source reported results and gave no indi-
cation that these results were either interim or prelimi-
nary, or that patient recruitment or data analysis would
continue. If the trial could not be classified as complete
after reviewing the most recent source, we searched for
the trial using the acronym or intervention on three
online databases (Clinical trials.gov http://www.clinical-
trials.gov, The Internet Stroke Center http://www.stroke-
center.org and Current Controlled Trials http://
www.controlled-trials.com. Trials were classified as com-
plete or ongoing depending on the status described by
these databases. If completion status remained unknown,
we attempted to contact investigators at least twice. If
investigators did not reply by 31st December 2008, the
trial completion status was classified as unclear.
Inclusion criteria
We included all completed randomised controlled trials
(RCTs) and controlled clinical trials (CCTs) of pharmaco-
logical interventions for acute ischaemic stroke which
were unpublished as of March 2009. Trials were labelled
as RCTs if they stated that participants or groups of par-
ticipants were randomly assigned to treatments. We
assumed that trials that were described as either double-
blind or placebo-controlled or both were randomised.
T rials were labelled as CCT s if they stated that partici-
pants or groups of participants were allocated prospec-
tively to different interventions using either a quasi-
random method, or if no method was described[13]. We
defined 'acute stroke' as a stroke assessed within 30 days
of symptom onset. We excluded trials which included
mixed populations of patients with acute and non-acute
stroke unless they reported results for patients with acute
s t r o k e  s e p a r a t e l y .  S i m i l a r l y ,  w e  e x c l u d e d  t r i a l s  w h i c h
included mixed populations of patients with ischaemic
and haemorrhagic stroke unless they reported results for
patients with ischaemic stroke separately. We excluded
trials which did not describe a control group.
Data extraction
One author (LG) extracted data on trial designs, meth-
od s,  a n d  r e s u l ts.  W e  r ec o r d ed  s a m p l e  s i z e ,  n u m be r  o f
centres, type of intervention, comparison groups, method
of randomisation, blinding procedures, and allocation
concealment for each trial. If details were unclear, trial
sources were referred to a second author (PS and/or MB).
We classified trials as single or multi-centre according to
descriptions provided by investigators. If such descrip-
tions were not available, we noted investigators' institu-
tional affiliations and arbitrarily classified trials with one
affiliated hospital or clinic as single centre, and trials with
more than one affiliated hospital or clinic as multi-centre,
accepting that in rare instances, investigators from multi-
ple hospitals or clinics would participate but only one
centre would be responsible for recruiting patients.
We extracted all available data on treatment effects on
clinical outcomes (e.g. death, death or dependency and
adverse effects) and on non-clinical outcomes (e.g. physi-
ological variables or laboratory measures of uncertain
clinical significance). We classified results as qualitative
or quantitative and noted whether statistical significance
was reported. We extracted data on the most important
clinical outcome reported, such as death or functionalGibson et al. Trials 2010, 11:43
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scales, from the most recent source. In the absence of
data on death or dependency, we extracted data on the
studies' pre-defined primary outcome. If no primary out-
come was defined, we extracted data on the first outcome
described in the methods.
We classified the reported effects of interventions as
beneficial, harmful, or neutral based on statistical signifi-
cance, or percentages of participants having a particular
outcome if statistical data were not available. We defined
trials as beneficial if the intervention was reported to
have had a favourable effect compared with the control
treatment; as harmful if the treatment effect was adverse;
and neutral if no differences were reported between
intervention and control groups. Where only quantitative
results were available but statistical data were not pro-
vi d ed ,  w e  c l as s i f i ed  t ri a ls  as  n e u t r a l  o n l y  i f  t h e  r es u l ts
were exactly the same for each intervention group.
Where results were available for different time points, we
recorded only the latest time point. We classified results
as 'unable to analyse' if results were not reported sepa-
rately for each intervention group.
We also extracted data on the number and type of
sources reporting a trial, the investigators, country of ori-
gin, funding, and date of the latest source. If an investiga-
tor appeared to have been involved in multiple completed
but unpublished trials, we cross-referenced their institu-
tional affiliation in the sources for the different trials. We
contacted investigators if it was still unclear whether they
had been involved in multiple trials. We used the institu-
tional affiliation of the first investigator of the latest
source to determine the country of origin of each trial.
We classified trials as receiving funding from pharmaceu-
tical companies when this was explicitly stated in a source
or if any of the investigators were affiliated to a pharma-
ceutical company.
If any of these data could not be extracted from the
most recent source, we checked earlier sources. If data
w e r e  s t i l l  n o t  a v a i l a b l e ,  t h e y  w e r e  c l a s s i f i e d  a s  n o t
reported.
Calculating the prevalence of unpublished studies
We did not have the resources to fully check the eligibility
of each of the published studies. We therefore estimated
the proportion that would not meet all our eligibility cri-
teria by assessing in detail a random 20% sample of the
published studies. We listed published studies by date of
most recent publication, and used random.org [14] to
select 20% of studies in each of the following date ranges:
1980-1984, 1985-1989, 1990-1994, 1995-1999, 2000-
2004, 2005-2009, pre-1980 and unknown date. The per-
centage of published studies which otherwise met the
inclusion criteria (which we term 'eligible published stud-
ies') was calculated and applied to the entire list of pub-
lished studies. To calculate the point prevalence of
unpublished studies, we divided the number of unpub-
lished studies by the sum of the number of unpublished
studies and the number of eligible published studies. We
used the normal approximation method to calculate 95%
confidence intervals (CI) [15].
Results
The prevalence of completed but unpublished trials
The search identified 940 trials of pharmacological inter-
ventions for acute ischaemic stroke of which 125 [16-130]
(Castillo J: Cooling therapy for acute stroke, unpublished,
Chen O: Batroxobin (DF-521) in the treatment of acute
cerebral infarction, unpublished, Egberts JFM, Sommer
W: Multicentre, randomised, assessor-blind, dose-com-
parative study of org 10172 (orgaron (r)) in the treatment
of acute ischaemic stroke, unpublished, Garcia Tigera J,
Avarez LG, Hernandez MO: Treatment with calcium
c h a n n e l s  b l o c k e r s  ( n i f e d i p i n e )  o f  p a t i e n t s  w i t h  a c u t e
brain infarction, unpublished, Geeganage C, Bath PMW:
An assessment of the effects of altering blood pressure on
cerebral and systemic haemodynamics in patients with
acute ischaemic stroke, unpublished, UCB Pharma:
Piracetam vs placebo in the acute treatment of acute
ischaemic supratentorial cerebrovascular accidents: pilot
study, unpublished, Bath P: Dose escalation study of dob-
utamine in acute stroke patients, unpublished, Utsumi H:
Evaluation of the use of ticlopidine, an antiplatelet agent,
in acute cerebral infarction, unpublished) were complete
but unpublished by March 23rd 2009 and were included in
this review (Figure 1). Note that two of the references to
the 125 included trials reported two trials each. Our sam-
ple of 20% of the published studies identified 21/124
(16.9%) which failed to meet inclusion criteria. Two stud-
ies did not test pharmacological interventions, three
studies did not involve patients with acute stroke, four did
not test interventions for stroke (one study was a second-
ary prevention trial and three investigated treatment for
deep vein thrombosis in patients with stroke), and the
remaining 12 studies did not appear to be either CCTs or
RCTs. Assuming 16.9% of published studies were ineligi-
ble, we estimate that of the 618 published studies, 104
were ineligible published studies and 514 were eligible
published studies. The point prevalence of unpublished
studies was 19.6% (125/(125+514), 95% CI 16.5-22.6%).
Available data on design of unpublished trials
Of these 125 trials, 112 (89.6%) provided the number of
enrolled patients with acute ischaemic stroke (16,058
patients) on whom 89 different pharmacological inter-
ventions were tested (Figure 2).
Amongst the 112 trials that provided the number of
participants, the mean sample size was 143.4. Two trials
included fewer than 10 patients each, and the largest trial
included 856 patients (See Additional file 1: Trials whichGibson et al. Trials 2010, 11:43
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included 100 or more patients). Seventy-two trials
included 99 patients or fewer, and 40 trials included 100
patients or more, of which eight trials included over 500
patients. Seventy-three trials reported the number of
patients in each treatment group, giving a mean of 60.6
participants per group, with a mode of 2 groups per trial.
There were 50 (40.0%) multi-centre trials and 55 (44.0%)
single centre trials. We could not determine the number
of centres for 20 (16.0%) trials.
Each of the 89 different interventions was investigated
by a mean of 1.4 trials (range 1-4, mode 1). Arundic acid,
also known as ONO-2506, was investigated by four trials.
Seven interventions were investigated by three trials each
(cerebrolysin, emoxipin, GM1, insulin, low molecular
weight heparin, piclozotan, and piracetam). The 40 trials
which included over 100 patients investigated 34 different
interventions, with five interventions being tested by two
trials each (arundic acid/ONO-2506, eliprodil, GM1,
heparin, and piracetam).
Sixty-seven (53.6%) trials were placebo-controlled, of
which 23 recruited over 100 patients. The remaining tri-
als used either open controls (n = 29, 23.2%), or the con-
trols received another drug (n = 28, 22.4%). One trial
initially stated that controls received placebo and later
reported that they received 'conventional treatment'
within the only available source.
Details on randomisation, blinding procedures, and
allocation concealment methods were often insufficient.
Only seven (5.6%) trials - three trials involving over 100
patients - reported the method of randomisation or the
Figure 1 Trials flowchart.
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Figure 2 Actual sample sizes of completed but unpublished trials.
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allocation to intervention groups. Sixty-eight (54.4%) tri-
als reported their blinding procedures: 10 (8.0%) were
single-blind and the remaining 58 (46.4%) were double-
blind. Of the 40 trials which recruited over 100 patients,
three (7.5%) were single-blind and 21 (52.5%) were dou-
ble-blind. Just four (3.2%) trials, two of which recruited
over 100 patients, reported the method of allocation con-
cealment (See Additional file 1: Trials which included 100
or more patients). Only 29 (23.2%) trials reported the trial
phase (mode phase II, range I-III).
Available data on results of unpublished trials
Of the 125 included trials, 98 (78.4%) trials reported some
outcomes. Only 22 (17.6%) trials reported deaths, having
recruited 4,251 patients of whom 636 (15.0%) died. Only
6 (4.8%) trials reported the number of patients who either
died or became dependent, with a total of 663 dead or
dependent patients.
Adverse effects were observed in 40 (32.0%) trials, in 11
(8.8%) trials no adverse effects were noted, and 54 (43.2%)
did not provide information on adverse effects. The
remaining 20 (16.0%) trials did not provide findings.
We were able to extract data on outcomes reported at
the end of the study period for 101 (80.8%) trials. Four
(3.2%) trials reported only interim results and 20 (16.0%)
trials did not provide any outcome data. Five of the 105
trials which reported outcomes did not provide results
according to intervention group, leaving 100 trials with
potentially analysable results (Table 1) of which 99 pro-
vided information on outcome measures. The overall
findings of the European Eliprodil trial were only
reported in the medical press without details of the out-
comes measured in the trial[131].
Available data on other characteristics of unpublished trials
Investigators
We noted 551 different investigators as authors of com-
pleted but unpublished trials. The mean number of inves-
tigators per trial was 5.3 (range 0-18, mode 1). Two trials
were investigated by a named group, and the number of
investigators for these two trials was classified as 0. Sev-
enty-two different investigators were authors of multiple
trials (three were authors of four separate unpublished
trials each).
Country of origin
Completed but unpublished trials were performed by
investigators based in 23 different countries (Figure 3).
Only 43 (34.4%) trials reported their source of funding.
Thirty-nine trials were funded by pharmaceutical compa-
nies and four by other agencies.
Sources of information about unpublished trials
Data from unpublished trials was obtained from 238
sources, including 160 (67.2%) abstracts and 78 (32.8%)
non-abstract sources such as press releases, letters to edi-
tors, protocols, correspondence with investigators, corre-
spondence between investigators and ethics committees,
online trials registers, pharmaceutical company reports,
and university websites. The mean number of sources per
trial was 1.9 (range 1-6, mode 1) with a mean of 1.3 (range
0-5, mode 1) abstracts per trial and a mean of 0.6 (range
0-4 mode 0) non-abstract sources per trial. Fifteen trials
were not reported in abstracts. Five trials were identified
through online trials registers alone.
Dates of most recent report from each unpublished trial
The number of completed but unpublished trials has
increased steadily (Figure 4).
Table 1: Characteristics of available data in completed but unpublished trials*
Beneficial (n = 56)
n (%)
Harmful (n = 7)
n (%)
Neutral (n = 37)
n (%)
Results
Final results 54 (96.4) 6 (85.7) 36 (97.3)
Interim results 2 (3.6) 1 (14.3) 1 (2.7)
Clinical outcomes 40 (71.4) 7 (100) 32** (86.5)
Non-clinical outcomes 16 (28.6) 0 (0) 4 (10.8)
Statistical significance
Statistics reported 24 (42.9) 1 (14.3) 7 (18.9)
Statistics not reported 32 (57.1) 6 (85.7) 30 (81.1)
Nature of results
Quantitative 31 (55.4) 7 (100) 13 (35.1)
Qualitative 25 (44.6) 0 (0) 24 (64.9)
*Only 100 trials are included in the table as 20 did not report any results and 5 did not report results separately for each treatment group and 
were classified as unable to analyse.
** One trial reported results in the medical press, but the outcome measure was not described.Gibson et al. Trials 2010, 11:43
http://www.trialsjournal.com/content/11/1/43
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Figure 3 Country of origin of completed but unpublished trials. Country of origin was determined from the institutional affiliation of the first in-
vestigators listed in the most recent source from each trial.Gibson et al. Trials 2010, 11:43
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Discussion
Key findings
We have demonstrated that an important minority of
completed clinical trials are not reported in full, several of
which may be large enough to influence clinical practice
and the findings of systematic reviews and meta-analyses.
Prevalence of completed but unpublished trials in other 
studies
Estimates of completed but unpublished trials in a range
of medical fields are much higher than the estimate of
this review of acute stroke trials (19.6%). It is difficult to
judge if the results of this review of trials in acute stroke
are representative of publication practices in other areas
of the medical literature (other studies on this question
are limited), but we are not aware of any reasons to
expect that they would be substantially different. Blumle
and colleagues[7] found that 47.6% (49/103) of trials sub-
mitted to a German research ethics committee (REC) in
2000 were not published by 2007[7]. Peinemann and col-
leagues[132] identified 13 trials of negative pressure
wound therapy, a type of wound dressing, of which four
(30.8%) were unpublished[132]. The difference between
estimates may be explained by the small sampling frames
used in these studies compared to our review. We used
the Cochrane Stroke Group's Specialised Register of Tri-
als, an extremely large collection of stroke trials[11] as the
sampling frame. It is the result of a comprehensive search
strategy which includes bibliographic databases, trial reg-
istry websites, hand-searching of journals, conference
proceedings, press releases, correspondence with investi-
gators and information from pharmaceutical compa-
nies[12]. There are no language restrictions in the
Register which has minimised the risk of selection bias.
Our findings are further strengthened by the system we
used to determine the completion status of trials. Previ-
ous studies failed to determine completion status of trials
so ongoing trials may have been misclassified as unpub-
Figure 4 Year of most recent report from completed but unpublished trials. Only 123 trials are included in the figure as we were not able to 
determine the date of the most recent report for two trials.Gibson et al. Trials 2010, 11:43
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lished[4,6,9]. Using trial sources, online registers, consul-
tation with an expert and contacting investigators as a
last resort, enabled us to determine the completion status
of 165 of the 184 trials which met the inclusion criteria.
We identified 40 completed but unpublished trials
which had each involved over 100 patients, with eight
including over 500 patients each. Large trials are given
more weight in meta-analyses, and have greater potential
to change clinical practice[133]. The assessment of trial
methodological features (e.g. sample size, methods of
randomisation, blinding procedures, allocation conceal-
ment) is required to decide whether a trial is of sufficient
quality for inclusion in a systematic review, meta-analy-
sis, or clinical practice guideline[133,134], but few trials
reported sufficient study details to allow methodological
quality to be assessed.
How can authors be encouraged to publish trials more 
fully? The implications of this review
Initiatives to encourage investigators to disclose unpub-
lished trials have been unsuccessful. Only 165 brief
reports of unpublished trials had been submitted to the
Medical Editors' Trials Amnesty after one year[135]. A
survey of over 40,000 obstetricians revealed just 18
unpublished trials which had been completed at least 2
years previously[136].
RECs, journals and government could help to encour-
age investigators to publish clinical trials [137-139]. In the
UK, it is recommended that RECs require investigators to
declare their intent to publish, but it is not yet mandatory
(Hugh Davies, unpublished data, 2008). RECs could act at
three different stages of clinical trials to encourage publi-
cation of the results. Firstly, RECs could require investiga-
tors to intend to publish the results[137] when the trial is
submitted for ethical approval. Secondly, as RECs cur-
rently require investigators to outline a plan of research
dissemination [140], they could also request regular
updates on the progress of publication after trial comple-
tion. Finally, RECs could elicit investigators' reasons for
failing to publish results[137] if trials have not reached
the public domain within a reasonable time.
Journals have taken steps to encourage investigators to
submit reports of trials. Cancer Epidemiology, Biomark-
ers and Prevention created a section entitled 'Null Results
in Brief'[141]. The journal Pediatrics announced that
publication of a trial protocol would come with a provi-
sional acceptance of the complete trial report for publica-
tion[138]. Journals dedicated to publishing null results
now exist, including the Journal of Negative Results in
Biomedicine[142]. Established journals could create sec-
tions for short reports of trials with null results, and with
the development of online publishing, creating space for
additional publications has become less of an issue[139].
Prospective registration of clinical trials may help to
hold investigators to account for publishing results[139].
Only five trials were identified using online registers
alone, suggesting that currently, prospective registration
can assist in indentifying unpublished trials, but should
not be used as the primary method of locating unpub-
lished trials. Although the CONSORT statement sup-
ports prospective trial registration[143], and many
journals have become signatories to the statement[144], it
is not clear how often journals use prior registration of a
trial as a pre-requisite for publication of the results paper.
Chalmers suggests that government regulation is also
required to improve the reporting of clinical trials[145].
In March 2008, the National Research Ethics Committee,
the James Lind Alliance, and the Department of Health
announced a joint project called 'Mind the Gap' (Linda
Burridge, unpublished data, 2008) with the International
Standard Randomised Controlled Trials Number Register
and clinicaltrials.gov to improve the completeness of clin-
ical trial registration, and to improve the dissemination of
trial results[146]. The project is due to be completed by
the end of 2008[146]. Both Italy and America have made
comprehensive information on clinical trials publicly
accessible[146,147]. Registration of clinical trials investi-
gating drugs and devices subject to approval from the
Food and Drug Administration and reporting of basic
results online has been a legal requirement in the United
States since 2007 [147], but the governments of other
countries could follow suit in an international effort to
reduce non-publication of clinical trials.
Limitations
We were unable to determine the status of 19 trials and
some may be completed but not published. The status of
some trials may have been misclassified if the online trials
registers were not up to date. We used the online registers
to classify the status of 8 included trials, so any misclassi-
fication through using these registers is minimal. Also,
the number of centres of some trials may have been mis-
classified.
We may have overestimated the prevalence of unpub-
lished trials by including trials which were completed
within the last three years and trials with very small sam-
ple sizes (two trials included fewer than ten patients
each). It may be unreasonable to expect such trials to be
published. We included all trials completed up to March
2009, and reported point prevalence, as there are now
opportunities simultaneously to present trials at confer-
ences and publish them in a journal. The estimates of the
proportion of patients who died, were dead or dependent
and who suffered adverse effects are of interest, but may
not be reliable as the sources available to us rarely
reported these data.Gibson et al. Trials 2010, 11:43
http://www.trialsjournal.com/content/11/1/43
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Conclusions
In this review, 19.6% of the clinical trials identified from
the register were completed but not published in full.
These data represent a substantial body of evidence that
is of relevance both to clinical practice in acute stroke and
to future research in the field, yet is not fully publicly
available. Responsibility for non-publication lies with
investigators, but pharmaceutical companies, research
ethics committees, journals and governments can all play
a part in ensuring that the results of RCTs are made pub-
licly available within a reasonable interval of trial comple-
tion.
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Tissue plasminogen activator; UK: United Kingdom; USA: United States of
America.
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